Results 41 to 50 of about 645 (131)

Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial

The Lancet. Healthy Longevity
Summary: Background: Observational studies show inverse associations between serum 25-hydroxyvitamin D concentrations and sarcopenia incidence; however, it remains unclear whether treatment with vitamin D prevents its development.
Tetsuya Kawahara, MD, Gen Suzuki, ProfMD, Shoichi Mizuno, PhD, Naoki Tominaga, MD, Mikio Toda, MD, Nagahiro Toyama, MD, Tetsuya Inazu, ProfMD, Chie Kawahara, MD, Yosuke Okada, MD, Yoshiya Tanaka, ProfMD   +9 more
doaj   +1 more source

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis

Osteoporosis and Sarcopenia, 2019
Objectives: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor response ...
Mikio Kamimura, Shota Ikegami, Keijiro Mukaiyama, Hidefumi Koiwai, Yukio Nakamura, Akira Taguchi, Hiroyuki Kato   +6 more
doaj   +1 more source

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database

Pharmaceuticals, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is associated with many drugs, including bisphosphonates (BPs). BPs are associated with atypical femoral fractures and osteonecrosis of the external auditory canal.
Shinya Toriumi, Akinobu Kobayashi, Yoshihiro Uesawa   +2 more
doaj   +1 more source

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study

Osteoporosis and Sarcopenia, 2019
Objectives: Increasing bone mineral density (BMD) to reduce fracture risk is a primary goal of osteoporosis treatment. This prospective, observational study evaluates the effects of monthly minodronate (MIN; 50 mg) with or without eldecalcitol (ELD ...
Takako Suzuki, Yukio Nakamura, Hiroyuki Kato   +2 more
doaj   +1 more source

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis

Journal of Orthopaedic Surgery and Research, 2020
Background Osteoporosis is a metabolic bone disease. Bisphosphonate (BP) and eldecalcitol (ELD) are two clinical first-line drugs for osteoporosis patients. However, the effect of ELD + BP vs. BP alone on osteoporosis treatment is still unclear.
Zaoqian Zheng, Jinyu Luo
doaj   +1 more source

SPIRIT checklist

, 2022
The document indicates the SPIRIT checklist for the  protocol: a randomized study of the efficacy of ibandronic acid plus eldecalcitol in patients with gastric cancer after gastrectomy: A comparative study of different routes of administration of ...
Hisaki Aiba (12989435)
core   +1 more source

Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway

Stem Cell Research & Therapy, 2022
Background The incidence of diabetic osteoporosis is increasing. This article evaluates the effect of combination treatment with the hypoglycemic drug exendin-4 (Ex-4) and the vitamin D analog eldecalcitol (ED-71) on improving diabetic osteoporosis and ...
Yupu Lu, Shanshan Liu, Panpan Yang, Yuying Kou, Congshan Li, Hongrui Liu, Minqi Li   +6 more
doaj   +1 more source

Serious: Non-serious ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

case report form.xlsx

, 2022
The data includes the sample of case report in the protocol article: a randomized study of the efficacy of ibandronic acid plus eldecalcitol in patients with gastric cancer after gastrectomy: A comparative study of different routes of administration of ...
Hisaki Aiba (12989435)
core   +1 more source

High prominence:Low prominence ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source